A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
Status:
Completed
Trial end date:
2019-02-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the benefit of enzalutamide versus placebo as
assessed by overall survival and progression-free survival in patients with progressive
metastatic prostate cancer who have failed androgen deprivation therapy but not yet received
chemotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Medivation, Inc. Pfizer
Collaborators:
Astellas Pharma Inc Medivation LLC, a wholly owned subsidiary of Pfizer Inc.